Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 1of 22
NON- INTERVENTIONAL (NI) STUDY PROTOCOL
Study Information
Title Effect of Trumenba onGonococcal infections in 
adolescents and young adults in the United 
States: A retrospective cohort study
Protocol number B1971066
Protocol version identifier 1.0
Date 18 April 2023
Medicinal product Trumenba 
Research question and objectives To examine the effect of Trumenba on
gonococcal infection in adolescents and young 
adults in the United States using a claims 
database.
Author (Pfizer) : 
(Pfizer): 
(Pfizer):
(Pfizer): 
This document contains confidential information belonging to Pfizer. Except as otherw ise agreed to in w riting, 
by accepting or reviewing this document, you agree to hold this information in confidence and not copy or 
disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event 
of any actual or suspected breach of this obligation, Pfizer must be promptly notified.
PPD
PPD
PPD
PPD
PPD
PPD
PPD

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 2of 221.TABLE OF CONTENTS
1. TABLE OF CONTENTS ................................................................ ................................ .......2
2. LIST OF ABBREVIAT IONS ................................................................................................4
3. RESPONSIBLE PARTI ES....................................................................................................6
4. ABSTRACT ...........................................................................................................................7
5. AMENDMENTS AND UP DATES .......................................................................................8
6. MILESTONES .......................................................................................................................9
7. RATIONALE AND BAC KGROUND ................................................................................10
8. RESEARCH QUESTION AND OBJECTI VES .................................................................11
8.1. Objectives ................................................................................................................11
8.1.1. Primary  Objective .......................................................................................11
8.1.2. Secondary Objecti ves................................
.................................................11
8.1.3. Exploratory  Objectives ...............................................................................11
9. RESEARCH METHODS ................................
....................................................................11
9.1. Study  Design ................................ ................................ ................................ ........... 11
9.2. Setting ......................................................................................................................12
9.2.1. I nclusion Criteria ........................................................................................12
9.2.2. Exclusion Criteria .......................................................................................12
9.3. Variables ..................................................................................................................12
9.4. Data Sources ............................................................................................................17
9.5. Study  Size ................................................................................................................17
9.6. Data Management ...................................................................................................18
9.7. Data Anal ysis..........................................................................................................18
9.8. Quality  Control ........................................................................................................18
9.9. Strengths and Limitations of the Research Methods ................................ ............... 19
9.10. Other Aspects ........................................................................................................19
10. PROTECTI ON OF HU MAN SUBJECTS ................................ ................................ ........ 19
10.1. Patient I nformation ................................................................................................19
10.2. Patient Consent ................................
......................................................................19
10.3. I nstitutional Review Board (IRB)/Independent Ethics Committee (I EC)............19
10.4. Ethical Conduct of the Study ................................................................................20

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 3of 2211. MANAGEMENT AND REPORTI NG OF ADVERSE EVENTS/ADVERSE 
REACTI ONS ................................................................ ................................ ...................... 20
12. PL ANS FOR DI SSEM INATING AND COMMUNI CATING STUDY RESUL TS........20
13. REFERENCES ..................................................................................................................21
14. LIST OF TABLES .............................................................................................................22
15. LIST OF FIGURES ...........................................................................................................22
ANNEX 1. LIST OF STAND ALONE DOCUMENTS
.........................................................22

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 4of 222.LIST OF 
ABBREVIATIONS
Abbreviation Definition
4CMenB bexsero vaccine
CIOMS International Ethical Guidelines for Ep idemiological 
Research issued b y the Council for International 
Organizations of Medical Sciences
CFR Code of Federal Regulations
CPT current procedural terminology
EMA European Medicines Agency  
ENCePP European Network of Centres for 
Pharmacoepidemiol ogyand Pharmacovigilance
FDA Food and Drug Administration
fHBP factor H binding protein
GEP Good Epidemiological Practice
GPP Good P harmacoepidemiology  Practices
HRs hazard ratios
HIPAA Health Insurance Portability  and Accountability  Act
HIV human i mmunodeficien y virus
ICD-10-CM International Classification of Diseases , 10th
Revision, Clinical Modification
IEA International Epidemiological Association
IEC Independent Ethics Committee
IRB Institutional Review Board
ISPE International Societ y for Pharmacoepidemiology
ISPOR Good Outcomes Research Practices issued b y the 
International Society for Pharmacoeconomics and 
Outcomes Research
MenB Meningococcal Serogroup B
MSM men who have sex with men
NDC National Drug Codes
OMV outer membrane v esicle
PASS Post-Authorization Safety  Study

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 5of 22Abbreviation Definition
SAS statistical analysis system
US United States
VE Vaccine effectiveness

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 6of 223.RESPONSIBLE PARTIES
Principal Investigator (s)of the Protocol
Nam e, degree(s) Job 
Title Affiliation Address
Myint Tin Tin Htar Epidemio logy Lead Pfizer 23-25 Avenue Docteur 
Lannelongue 75014 
Paris, France
Mohamm ad Ali , PhD Statistician Pfizer 500 Arcola Rd 
Collegeville, PA
Angela Quinn , BS Clincal Scientist Pfizer 500 Arcola Rd 
Collegeville, PA 
Sarah Jeanette Willis Director, Vaccine s
RWE ScientistPfizer Remote,  
PPD

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 7of 224.ABSTRACT
Not required.

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 8of 225.AMENDMENTS AND UPDAT ES
None .

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 9of 226.MILESTONES
Milestone Planned date
Start of data collection 20April 2023
End of data collection 30 April 2023
Final study report 31October 2023

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 10of 227.RA
TION ALE AND BACKGROUND
This study  is not a Post -Authorization Safety  Study (PASS) and is not a commitment to any  
regulatory  authorit y.
Meningococcal B o
uter membrane v esicle (OMV) vaccines have been created, deve loped 
and used to control outbreaks of meni ngococcal B diseases in New Zealand, Norway  and 
Cuba. 
Studies suggested that OMV vaccines could potentially  protect against gonococcal 
infections in New Zealand and Norway .1
Recently  4 studies described the effe ct of Bexse ro(4CMenB) on gonococcal infection in 
adolescents and young adults (2 studies in the United States ( US), 1in Australia and 1in 
Italy). The vaccine coverage differed b y studies (69% in Australia, 33% in men who have sex 
with men ( MSM )living w ith h
uman i mmunodeficien cy virus ( HIV)in Italy  and 1.8% in 
New York Cit y& Philadelphia. The direct effect of 4CMenB (vaccine effectiven ess) ranged 
from 32 to 74% for 2 full doses and 33 to 71% for at least 1dose.2-5
Abara et al studied the effectiveness of 4CMenB and factor H b
inding protein ( fHbp )
vaccines in 2separate studies using the same methodology  in New York and Philadelphia 
regions for the period of 2016-2018 (t he first 2 years of meningococcal serogroup B [MenB] 
vaccines use in the US). The vaccine coverage was 7.4% and 1.6% for at least one dose for 
4CMenB and fHbp vaccines r espectively . The effectiveness of 4CMenB was 40% (95% CI 
23; 53) for full dose an d
26% (95% CI 12; 37) for only  1 dose. The effectiveness of fHbp 
vaccine was 3% (95%CI: +19; 21) .66These results were based on data during the period 
where fHbp had extremely  low vaccine coverage (<2%). 
Thevaccin
eeffectiveness for 4CMenB varied highly  according to study  types, age of the 
study  population and the vaccine coverage rate. T he vaccine coverage had increased to 
32% f or any MenB vaccines in 2021 while it was 14% and 17% in 2017 and 2018 
respectivel y.The effectiveness of fHbp vaccine observed in Abara et al stud ycould be 
confirmed in a larger population with higher vaccine coverage. The pu rpose of the study  will 
be to evaluate the effect of fHbp vaccine in prevention of gonococcal infection among 
15-30 years in the U S using the claim database . 

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 11of 228.RESEARCH QUESTION AND OBJECTIVES
8.1.Objectives
8.1.1. Primary Objective
To examine the effect of at least 1dose of Trumenba ongonococcal infection in adolescents 
and y oung adults of 15
-30 years in the US.
8.1.2. Secondary Ob jectives 
1. To examine the effect of at least 2doses of 
Trumenba ongonococcal infection in 
adolescents and young adults of 15-30 years in the U S.
2.To 
examine the effect of at least 1dose of Trumenba on chlam ydial infection in 
adolescents and young adults of 1 5-30 years in the U S.
3.To 
examine the effect of at least 2doses of Trumenba onchlam ydial infection in 
adolescents and young adults of 15- 30 years in the U S.
8.1.3. E xploratory O bjectives
1. To examine the effect of at least 1dose of Trumenba ongonococcal inf ection in 
adolescents and young adults of 1 6-23 years in the U S.
2.
To examine the effect of 1dose of Trumenba on gonococcal infection in adolescents 
and y oung adults of 15- 30 years in the U
Sat 12 months, 24 months, 36 months and 
48 months following the index vaccination .
9. RESEARCH METHODS 
9.1.Study Design
This is a retrospective cohort study  using health care administrative claims data as described 
in Section 9.4 Data Sources .
Adolescents and young adults approximately 15 to 30 y ears of age at their individual time 
zero (calculated based on birth y ear)
will be identified from administrative claims during 
01January  2016 and 31 December 2021.
The exposure cohort will be th eindividuals who have received at least 1dose o f Trumenba 
and at least 1 dose of MenACWY (MenactraÂ®, MenveoÂ®, or MenQuadfiÂ®) prior to the 
Trumenba vaccination, between 01 January  2016 and 31 December 2021. The index date 
(zero time) for the exposed cohor tisthe last date of vaccination, and the cohort will be 
followed from 14 day s after vaccination to the end of the study  period (31 December 2022). 
The individuals in the cohort will be censored b y the event of interest , death date (if known), 
plan disenr ollment (if known) or the end of the study period , whichever comes first .

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 12of 22The reference cohort will be those with at least 1
dose of MenACWY vaccine, but no doses 
of Trumemba during the observation period , received between 01January  2016 and 
31December 2021. The MenACWY -only vaccinated cohort is used as a reference cohort 
rather than an unvaccinated cohort in order to help control for theoretical differences in 
health seeking and risk behaviors between vaccinated and unvaccinated individuals .The 
index da te (zero time) of the reference cohort is the last dose of MenACWY and these 
individuals will be followed from 14 day s after zero time until the earliest occurrence of the 
following: outcome of interest, death date (if known), plan disenrollment (if known) or 
31December 2022 (end of study  period). 
The outcomes of interest are gonococcal and chlamy dial infections and only the first episode
within the study  period will be considered as event in case of repeated infections. 
9.2. Setting
IQVIA PharMetricsÂ®Plus is a longitudinal health plan database of adjudicated medical and 
pharmacy  claims, including patient enrollment data for national and sub -national health plans 
and self -insured employer groups in the US. Administrative claims and enrollment data 
available durin g 01 January  2016 and 31 December 2022 will be used in this study .
9.2.1. Inclusion Criteria
Patient records must meet all of the following inclusion criteria to be eligible for inclusion in
the study :
1.Individuals of approximately 15-30 years old (using July 1 ofbirth y ear)enrolled in a 
health plan available in PharMetrics Plus database during 01 January 2016 and 
31December 2021
.
2.Individuals having at least 1dose of MenACWY during 01 January  2016 and 
31December 2021.
9.2.2. E xclusion Criteria
Patients meeting any of the following criteria will not be included in the study :
Individuals having an y dose of Bexsero at an y time during 01 January  2016 and 
31December 2021 and prior to the study
Indiv iduals with missing demographic variables or dates of outcome diagno ses or vaccine 
administration (listed in Section 9.3). 
9.3.Variables
In this stud y, thevariables of interest are age, gender, state of residence, date of vaccination 
and the date of disease diag n
osis.

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 13of 22Table 1. Variable List
Variable Role Operational Definition
Birth Year Covariate Birth year (age to be 
calculated based on July
1 of birth year )
Gender Covariate Male, Female, Unknown
Residence (ZIP code) Covariate First 3digits of the zip 
code from individuals â€™
most recent enrollment 
MenACWY vaccination Non-exposure Current procedural 
terminology (CPT) codes 
and National Drug 
Codes (NDC) listed 
below
Trumemba vaccination Exposure CPT and 
NDCs listed below
Gono coccal infection Primary Outcome ICD- 10-CM codes listed 
below
Chlamydial infection Reference disease
OutcomeICD- 10-CM codes listed 
below

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 14of 22Table 2.
Diagnosis Codes for Identifying Gonococcal Infections
Code Type
A540 ICD-10-CM
A5400 ICD-10-CM
A5401 ICD-10-CM
A5402 ICD-10-CM
A5403 ICD-10-CM
A5409 ICD-10-CM
A541 ICD-10-CM
A542 ICD-10-CM
A5421 ICD-10-CM
A5422 ICD-10-CM
A5423 ICD-10-CM
A5424 ICD-10-CM
A5429 ICD-10-CM
A543 ICD-10-CM
A5430 ICD-10-CM
A5431 ICD-10-CM
A5432 ICD-10-CM
A5433 ICD-10-CM
A5439 ICD-10-CM
A544 ICD-10-CM
A5440 ICD-10-CM
A5441 ICD-10-CM
A5442 ICD-10-CM
A5443 ICD-10-CM
A5449 ICD-10-CM
A545 ICD-10-CM
A546 ICD-10-CM
A548 ICD-10-CM
A5481 ICD-10-CM
A5482 ICD-10-CM
A5483 ICD-10-CM
A5484 ICD-10-CM
A5485 ICD-10-CM
A5486 ICD-10-CM
A5489 ICD-10-CM
A549 ICD-10-CM

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 15of 22Table 3. Diagnosis Codes for Identifying Chlamydial Infections
Code Type
A55 ICD-10-CM
A560 ICD-10-CM
A5600 ICD-10-CM
A5601 ICD-10-CM
A5602 ICD-10-CM
A5609 ICD-10-CM
A561 ICD-10-CM
A5611 ICD-10-CM
A5619 ICD-10-CM
A562 ICD-10-CM
A563 ICD-10-CM
A564 ICD-10-CM
A568 ICD-10-CM
A71 ICD-10-CM
A710 ICD-10-CM
A711 ICD-10-CM
A719 ICD-10-CM
A74 ICD-10-CM
A740 ICD-10-CM
A748 ICD-10-CM
A7481 ICD-10-CM
A7489 ICD-10-CM
A749 ICD-10-CM

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 16of 22Table 4. Current Procedural Terminal Codes and National Drug Co des for 
Identifying MenACWY Vaccination
Code Type Description
90734 CPT Menactra/Menveo Vaccination
90619 CPT Menquadfi Vaccine
4928 1-0589-05 NDC Menactra Vaccine
46028 -0208 -01 NDC Menveo Vaccine
58160 -0955 -09 NDC Menveo Vaccine
49281 -0589 -58 NDC Menactra Vaccine
49281 -0590 -58 NDC Menquadfi Vaccine
46028 -0218 -11 NDC Menveo Vaccine
58160 -0958 -01 NDC Menveo Vaccine
58160 -0959 -01 NDC Menveo Vaccine
46028 -0219 -11 NDC Menveo Vaccine
54569 -5687 -01 NDC Menactra Vaccine
50090 -1890 -01 NDC Menactra Vaccine
49281 -0590 -05 NDC Menquadfi Vaccine
Table 5. Current Procedural Terminal Codes and National Drug Codes fo r
Identifying Trumemba (fHbp) Vaccination
Code Type Description
90621 CPT Trumenba Vaccination
00005 -0100 -01 NDC Trumenba Vaccine
00005 -0100 -02 NDC Trumemba Vaccine
00005 -0100 -05 NDC Trumenba Vaccine
00005 -0100 -10 NDC Trumenba Vaccine

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 17of 22Table 6. Current Procedural Terminal Codes and National Drug Codes for 
Identifying Bexsero 4CMenB Vaccination
Code Type Description
90620 CPT Meningococcal recombinant 
protein and outer membrane 
vesicle (OMV) vaccine, 
serogroup B (MenB -4C), 2 
dose s chedule, for 
intramuscular use
46028011401 NDC Bexsero vaccine
46028011402 NDC Bexsero vaccine
46028011411 NDC Bexsero vaccine
58160097602 NDC Bexsero vaccine
58160097606 NDC Bexsero vaccine
58160097620 NDC Bexsero vaccine
Additional detail s will be include in the Statistical Analy sis Plan (SAP) .
9.4.Data Sources
Thedata for this retrospective secondary  data analy sis is a large third part y payerdatabase, 
the IQVIA PharMetrics Plus (Pfizer 03 April 2023 version). PharMetrics Plus is a health plan
claims database comprised of fully  adjudicated medical and pharmacy  claims for more than 
210 million unique enrollees since 2006. Data contributors to the database are largely  
commercial health plans. I t is representative of the commerciall y insured US na tional 
population for patients under 65 years of age. It contains a longitudinal view of inpatient and 
outpatient services, prescription and office/outpatient administered drugs, costs, and detailed 
enrollment information. All data are compliant to the Hea lth Insurance Portability  and 
Accountability  Act (HI PAA) to protect patient privacy . The database is used in a variet y of 
life sciences and commercial effectiveness studies. Over 250 peer reviewed publications have 
used PharMetrics Plus data.
9.5.Study Size
This isan exploratory  study , thus no hy pothesis was generated. All eligible individual s will 
be included in the study .
For the sample size estimation, we wished to detect a vaccine effectiveness against 
gonococcal infection of 20% or more with an onset from 14 day s after receipt of both 
TRUMENBA and MenACWY. A Cox regression of the log hazard ratio on a covariate with 
a standard deviation of 1.50 to achieve 80% power at a 0.05 significance level to detect a 
regression coefficient equal to
-0.2200, we need a s ampl e of 15,669. The sample size was 
adjusted for an anticipated overall event rate of 0.0046. We will have 520,392 samples in the 
study  database illustrating that we have adequate samples to conduct the analy sis. 

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 18of 229.6.Data Management 
This study will use sec ondar y data collected in the PharM etrics Plus database, which is 
de-identified and HI PAA compliant. The data will be made accessible only  to individuals 
working on the current study . No attempt will be made to identify  individual patients, 
hospitals, or phy sicians. Analy ses will be conducted using Statistical Analy sis Sy stem ( SAS)
9.4 (SAS I nstitute, Cary , NC). 
The anal ytic files will include p erson -level data, including information on baseline 
demographic and clinical characteristics, s tudy outcomes, and vacci nation information as 
described in the v ariable section above . Data for this study  will be processed and managed by  
Pfizer, I nc., and all analyses will be performe
dby Pfizer .
9.7.Data Analysis 
The zero time is the date of Trumenba vaccination for the exposed group and the date of
MenACWY for the unexposed group . We will assess gonococcal infections that occurred 
between i) 14 day s after zero time and 365 day s ii) 14 day s after zero time and 730 day s, iii) 
14 day s after zero time and 1095 days, and iv) 14 days
after zero time and till end of the 
study  period (31Dec 2022). We will censor the data in the event of interest ,death date (if 
known), plan disenrollment (if known), target end date, or the end of the study period, 
whichever comes first. In descrip tive an alyses, we will fit Kaplan -Meier curves. We will also 
create unadjusted and covariate adjusted Cox proportional hazard regression models 
verify ing first that the proportionality  assumption was satisfied for all independent variables. 
Hazard ratios ( HRs) will be estimated b y exponentiation of the coefficient for the vaccine 
variable in these models, with vaccine effectiveness estimated as (1 â€“HR)Ã—100%. SEs for the 
coefficients will be used to estimate p values and CI s for the HRs. If a covariate does not
satisfy the assumption of proportionality , we will exclude the variable for the multivariable 
model and will perform the stratified analy sis using the covariate. 
Detailed methodology  for summary  and statistical anal yses of data collected in this study  
will 
bedocumented in a statistical analysis plan (SAP), which will be dated, filed and maintained 
by Pfizer . The SAP may  modify  the plans outlined in the protocol; any  major modifications 
of primary  endpoint definitions or their analy ses would be reflect ed in a protocol amendment.
9.8.Quality Control
Only  observed data will be used in measuring study  variables. It is anticipated that 
demographic information will be available for nearly  all individuals in the study  population. 
All other variables will be defined b ased on the presence of specific data (eg, diagnosis, 
procedure, and drug codes) in the anal ytic file; the absence of such data will be assumed to 
indicate the absence of the characteristic/event captured by  the variable.

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 19of 229.9.Strengths and Limitations of the 
Research Methods
Strengths 
A significant strength of observational retrospective anal yses is that they  provide a better 
understanding of the study  population in real world clinical practice as compared to the 
controlled conditions of a clinical trial.
Limitations
There are several limitations in this study . Given that this is an observational study  using 
health care administrative claims data, residual confounding due to missing or unmeasured 
information is possible. To examine this, we will assess the effe ct of meningococcal 
vaccination on another sexually  transmitted disease occuring, at the same age group, as 
reference disease outcome . If the HRs in an y of these models are less than 1.0, it would 
indicate that residual confounding exis ts and may  result i nadjustment of our vaccine 
effectiveness ( VE)estimates.
Second, health care administrative claims data will be available from 01 
January 2016
through 31 December 2022 . It is possible that some participants may have received a 
Trumenba vaccination prior t oJanuary 1, 2016 or during a period in which we do not have 
their claims data and be misclassified as unvaccinated with Trumenba . This may  
underestimate Trumenba vaccine effectiveness because the Men- ACWY -only cohort will 
include Trumenba vaccinated patie nts.
9.10. Other A spects
Not 
applicable .
10. PROTECTION OF HUMAN SUBJECTS
10.1. Patient 
Information 
This study  involves data that exist in anony mized structured format and contain no patient 
perso nal information . 
10.2. Patient C onsent
As this study  involves anony mized structu
red data,which according to applicable legal 
requirements do not contain data subject to privacy  laws, obtaining informed consent from 
patients by  Pfizer is not required.
10.3. Instit utional Review Board (IRB)/Independent Ethics Committee (IEC)
The study  databa ses will be de -identified prior to their release to study  investigators, as set 
forth in the corresponding Data Use Agreement. The study  databases have been evaluated 
and certified b y an independent third part y to be compliant with the HI PAA of 
1996 statis
ticalde-identification standards and to satisfy  the conditions set forth in Sections 
164.514 (a) -(b)1ii of the HI PAA Privacy  Rule regarding the determination and 

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 20of 22documentation o f statistically  de-identified data. Use of the study  databases for health 
services research is therefore full y compliant with the HI PAA Privacy  Rule and federal 
guidance on Public Welfare and the Protection of Human Subjects (45 Code of Federal 
Regulations [CFR] 46 Â§46.101) and IRB approval is not required. 
10.4. Ethical Conduct of the S
tudy
The study  will be conducted in accordance with legal and regulatory  requirements, as well as 
with scientific purpose, value and rigor and follow generall y accepted research practices 
described in Good Pharmacoepidemiology Practices (GPP) issued by  theInternational 
Society  for Pharmacoepidemiology  (ISPE), Good Epidemiological Practice (GEP) guidelines 
issued by  the International Epidemiological Association (IEA), Good Outcomes Research 
Practices issued b y the International Societ y for Pharmacoeconomics and Outcomes 
Research (ISPOR), International Ethical Guidelines for Epidemiological Research issued b y 
the Council for International Organizations of Medical Sciences (CIOMS), European 
Medicines Agency  (EMA) European Network of Centres for Pharmacoepidemi ology and 
Pharmacovigilance (ENCePP) Guide on Methodological Standards in 
Pharmacoepidemiology , and Food and Drug Administration (FDA) Guidance for Industry : 
Good Pharmacovigilance and Pharmacoepidemiologic Assessment, and FDA Draft Guidance 
for Industry  an
d FD A Staff: Best Practices for Conducting and Reporting of 
Pharmacoepidemiologic Safety  Studies Using Electronic Healthcare Data Sets and/or 
equivalent.
11.MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE 
REACTIONS 
This study  involves data that exist as structured data by the time of stud y start.
In these data sources, individual patient data are not retrieved or validated, and it is not 
possible to link (ie, identify  a potential association between) a particular product and medical 
event for an y individ ual. Thus, the minimum criteria for reporting an adverse event (AE) 
(ie,identifiable patient, identifiable reporter, a suspect product, and event) cannot be met.
12.PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS
Formal communication of the results o fthisresearch will be done b y Pfizer authors through 
peer-reviewed publication s. For all publications relating to the Study ,Pfizer will comply with 
recognized ethical standards concerning publications and authorship, including Section II -
â€œEthical Consi derat ions in the Conduct and Reporting of Researchâ€ of the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals, 
http://www.icmje.org/index.html#authorship, established by the International Committee of 
Medical Journal Editors.
In the even tof any prohibition or restriction imposed (eg, clinical hold) by an applicable 
competent authorit y in any area of the world, or if party responsible for collecting data from 
the participant is aware of an y new information which might influence the evalua tion of the 
benefits and risks of a Pfizer product , Pfizer should be informed immediately . 

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 21of 2213.REFERENCES
1.
Kuhdari P, Stefanati A, Lupi S, Valente N, Gabutti G. Meningococcal B vaccination: 
real-world experien ce and future perspectives. Pathog Glob Health. 201 6Jun-Jul;110(4 -
5):148- 56. doi: 10.1080/20477724.2016.1195072. Epub 2016 Jun 16. PMID: 27309042; 
PMCI D: PMC5072112.
2. Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley  R, Mitchell J, Lally  
N, Ahou re M, Deneh y E, Koehler A, Flood L, Marshall H. Eff ectiveness and impact of 
the 4CMenB vaccine against invasive serogroup B meningococcal disease and 
gonorrhoea in an infant, child, and adolescent programme: an observational cohort and 
case-control study . Lancet I nfect Dis. 2022 Jul;22(7):1011- 1020. doi: 10.1016/S1473-
3099(21)00754- 4. Epub 2022 Apr 12. PMID: 35427492.
3. Abara WE, Bernstein KT, L ewis FMT, Schillinger JA, Feemster K, Pathela P, Hariri S, 
Islam A, Eberhart M, Cheng I, Ternier A, Slutsker JS, Mba eyi S, Madera R, Kirkcaldy  
RD. Effectiveness of a s erogroup B outer membrane vesicle meningococcal vaccine 
against gonorrhoea: a retrospective observational study . Lancet Infect Dis. 2022 
Jul;22(7):1021- 1029. doi: 10.1016/S1473- 3099(21)00812-4. Epub 2022 A pr 12. PMI D: 
35427490.
4. Raccagni AR, Galli L , Spagnuolo V , Bruzzesi E, Muccini C, Bossolasco S, Ranzenigo 
M, Gianotti N, L olatto R, Castagna A, Nozza S. Meningococcus B Vaccination 
Effectiveness against Neisseria gonorrhoeae Infection in People L iving with HI V: a 
Case
-control Study . Sex Transm Dis. 2023 Jan 13. doi: 
10.1097/OL Q.0000000000001771. Epub ahead of print. PMI D: 36728240.
5. Bruxvoort KJ, Lewnard JA, Chen LH, Tseng HF, Chang J, Veltman J, Marrazzo J, Qian 
L. Prevention of Neisseria gonorrhoeae With Me ningococcal B Vaccine: A Matched 
Cohort Study  in So uther n California. Clin I nfect Dis. 2023 Feb 8;76(3):e1341- e1349. 
doi: 10.1093/cid/ciac436. Erratum in: Clin I nfect Dis. 2023 Jan 11;: PMI D: 35642527.
6. Abara WE, Bernstein KT, L ewis FMT, Pathela P, Islam A, Eberhart M, Cheng I, 
Ternier A, Sanderson Slutsker J, Madera R, Kirkcaldy R. Healthy vaccinee bias and 
MenB -FHbp vaccine effectiveness against gonorrhea. Sex Transm Dis. 2023 Mar 2. 
doi: 10.1097/OL Q.0000000000001793. Epub ahead of print. PMI D: 36863060.

Trumenba
B1971066 NON- INTERVENTIONAL STUDY PROTOCOL
Version 1.0 ,18 April 2023
PFIZER C ONFIDENTIAL
CT24- WI-GL02 -RF02 4.0 Non -Interventional Study Protocol Template For Secondary Data Collection Study
01-Jun-2022
Page 22of 2214.LIST OF TABLES 
Table 1. Variable List
Table 2. Diagnosis Codes for Identify ing Gonococcal Infections
Table 3. Diagnosis Codes for Identify ing Chlamy dial Infections
Table 4.
Current Procedural Terminal Codes and National Drug Co des for Identify ing 
MenACWY Vaccination
Table 5. Current Procedural Terminal Codes and National Drug Codes fo rIdentify ing 
Trumemba (fHbp) Vaccination
Table 6. Current Procedural Terminal Codes and National Drug Codes for Identify ing 
Bexsero 4CMenB Vaccination
15.LIST OF FIGURES
None.
ANNEX 1. LIST OF STAND ALONE DOCUMENTS
None.

Document Approval Record
Document Name:	






 	 !
Document Title:	






 	 !
Signed By: Date(GMT) Signing Capacity
$$ 	 !%!%	& '''(

$$ 	 ! %& %	 ,


 $$ 	 !
%!!%! -./
PPD
